Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Follow-Up Questions
GLMD 주식의 가격 성능은 어떻습니까?
GLMD의 현재 가격은 $1.49이며, 전 거래일에 decreased 1.08% 하였습니다.
Galmed Pharmaceuticals Ltd의 주요 사업 주제나 업종은 무엇입니까?
Galmed Pharmaceuticals Ltd은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Galmed Pharmaceuticals Ltd의 시가총액은 얼마입니까?
Galmed Pharmaceuticals Ltd의 현재 시가총액은 $8.1M입니다
Galmed Pharmaceuticals Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Galmed Pharmaceuticals Ltd에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 0명의 매수, 3명의 보유, 1명의 매도, 그리고 0명의 강력한 매도를 포함합니다
